Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products

Author(s):  Uttaro Elizabeth, Zhao Fang, Schweighardt Anne

Issue:  Sep/Oct 2021 - Volume 25, Number 5
View All Articles in Issue

Page(s):  364-371

Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Page 1
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Page 2
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Page 3
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Page 4
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Page 5
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Page 6
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Page 7
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Page 8

Download in electronic PDF format for $75

Abstract:  The Institute for Safe Medication Practices (ISMP) Do Not Crush List is a common resource for healthcare providers to determine whether an oral solid drug product can be manipulated. However, evidence is weak or missing for a number of immediate-release products. The purpose of this study was to perform an in-depth analysis of these products on the ISMP Do Not Crush List with the goal of removing unnecessary restrictions and providing conditional recommendations if needed. The ISMP Do Not Crush List was reviewed, and the products in question were identified if they were listed with “no reason” provided or “film-coated” as the only reason. A checklist of evaluation criteria was then developed and used for analysis, including special dosage form design, hazardous drug status, and stability and pharmacokinetics concerns. Appropriate references and search strategies were streamlined to perform the evaluation, and manufacturers were also contacted with a standard drug-information inquiry. A total of 20 “film-coated” tablets and 17 “no reason” drug products were identified and evaluated using the above process. The analysis revealed that 9 products are special formulations or high-risk products which indeed should not be crushed. Most of the remaining 28 products presented no risk or a low risk for crushing. Some products may require safety precautions during handling or timely administration of crushed powder to patients with increased monitoring for efficacy and safety. Two summary tables along with the conditional recommendations are provided for pharmacists and other healthcare providers to aid in clinical decision making. A checklist of evaluation criteria was developed and used to perform an in-depth analysis of 37 immediate-release products on the ISMP Do Not Crush List. A significant number of these products were found to be suitable for crushing based on conditional recommendations. Furthermore, the checklist and evaluation strategy present a framework for healthcare providers to assess crushability of any future immediate release oral solid drug products when there are no suitable alternatives.

Related Keywords: Institute for Safe Medication Practices, ISMP, drug safety, Do Not Crush list, immediate-release drugs, hazardous drugs, extended-release formulations, enteric-coated formulations, antineoplastic drugs, film-coated drugs, bioavailability, amorphous solid dispersions, compatibility, stability, drug quality, special dosage forms, crushability, manufacturer data, alternative dosage forms, droxidopa, tafenoquine succinate, Kaletra

Related Categories: EXCIPIENTS, LEGAL, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products
Uttaro Elizabeth
, Zhao Fang, Schweighardt Anne
Sep/Oct 2021
Pg. 364-371

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Institute for Safe Medication Practices Lifetime Achievement Award 2011
Trissel Lawrence A
Jan/Feb 2012
Pg. 54-56

Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3)
Bakhteyar Hamid
, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N
Sep/Oct 2017
Pg. 418-425

How to Develop and Maintain a Hazardous Drug List
Dillon L Rad
May/Jun 2019
Pg. 182-186

U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Nov/Dec 2016
Pg. 457-458

Formulation Optimization Study for an Immediate-Release Tablet
Kyriacos Soula
, Dimassi Hani
May/Jun 2009
Pg. 259-261

Stability of Venlafaxine Immediate-Release Suspensions
Donnelly Ronald F
, Wong Keith, Goddard Rob, Johanson Christel
Jan/Feb 2011
Pg. 81-84

Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis
Lyon Joanna
Nov/Dec 2012
Pg. 456-460

The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List")
Allen Loyd V Jr
, Ashworth Lisa D
Jan/Feb 2005
Pg. 44-46

Basics of Compounding for Hazardous Drugs, Part 4: Developing the Hazardous Drugs List and Containment Workstations
Allen Loyd V Jr
Mar/Apr 2007
Pg. 149-151

Basics of Compounding: The Revised "Not to Compound List"
Allen Loyd V Jr
Jan/Feb 2015
Pg. 57-58

Efforts to Combat Prescription Drug Abuse Should Not Limit Access to Compounded Pain Medications
Gilbert John A
Sep/Oct 2009
Pg. 400-403

Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
Jan/Feb 2020
Pg. 30-36

Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination
Allen Loyd V Jr
Nov/Dec 2006
Pg. 446-448

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Blankenship Cynthia E
Sep/Oct 2014
Pg. 379-380

Hazardous Drug Enteral Device: A Closed System Device for Crushing and Dispersing Hazardous Drug Tablets for Enteral Administration
Lopez C Vidal
, Rios GL Quito
Sep/Oct 2022
Pg. 358-362

Accuracy Considerations in Sterile Compounding
Akers Michael J
Mar/Apr 2017
Pg. 133-142

In Vitro Evaluation of Extemporaneously Compounded Immediate-release Capsules with Premixed Excipients, Based on the Biopharmaceutics Classification System (BCS) of the Drugs
Pinheiro Vanessa A
, Danopoulos Panagiota, Demirdjian Lara, Nogueira Rodrigo J L, Dubois Fanny
Sep/Oct 2013
Pg. 424-431

Erratum: Stability of Venlafaxine Immediate-Release Suspensions
Allen Loyd V Jr
Mar/Apr 2011
Pg. 175

Return to Top